HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Merimepodib

HCID 153241
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
198821-22-6
Standard SMILES
COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1
InChIKey
JBPUGFODGPKTDW-SFHVURJKSA-N
Molecular formula
C23H24N4O6
Average molar mass
452.5 g/mol
Monoisotopic mass
452.1695845

Overview

Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

Names & identifiers

Preferred name
Merimepodib
IUPAC
[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
English name
MeriMepodib, VI-21497, VX-497
Molecular formula
C23H24N4O6
Molecular weight
452.46

Names & synonyms

Merimepodib198821-22-6VX-497MMPD2ZL2BA06FUVI-21497VI-21,497DTXSID70173639Carbamic acid, ((3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)-, (3S)-tetrahydro-3-furanyl ester(3S)-oxolan-3-yl N-{[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate(3S)-oxolan-3-yl N-((3-(((3-methoxy-4-(1,3-oxazol-5-yl)phenyl)carbamoyl)amino)phenyl)methyl)carbamatecarbamic acid, [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester
Show more names
VI 21497Merimepodib (VX-497)Merimepodib (VI-21497Merimepodib, 10 mM in DMSOMeriMepodib, VI-21497, VX-497VX497VX 497MMPVI21497VI 21497HCV,Inhibitor,Merimepodib,HBV,Hepatitis C virus,Hepatitis B virus,VX497,VX 497,inhibit,MMPD[[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic acid (3S)-tetrahydro-3-furanyl ester
MERIMEPODIBUMRefChem:811132DTXCID6096130[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate(S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamateMFCD09837807Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl esterCHEMBL304087

Database identifiers

CAS
198821-22-6
PubChem CID
153241
DTXSID
DTXSID70173639
ChEMBL
CHEMBL304087
UNII
2ZL2BA06FU
Nikkaji
J1.291.375C

Properties

Computed structural propertiesFilling in

XLogP
2.1
Topological polar surface area
124 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
7
Rotatable bonds
8
Heavy atoms
33
Formal charge
0
Complexity
652

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP3.6

Physicochemical properties

Boiling point
571.4 · 571.4±50.0 °C(Predicted)
Density
1.36 · 1.36±0.1 g/cm3(Predicted)
storage temp.
Sealed in dry,Room Temperature
solubility
45.2 mg/mL · ≥45.2 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form
solid
pka
11.66 · 11.66±0.46(Predicted)
color
Off-white to light yellow
FDA UNII
2 ZL2BA06FU · 2ZL2BA06FU
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319
Precautionary statements
501 · P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319
Precautionary statements
P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

Merimepodib, an oral drug, contains a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme responsible for stimulating the production of lymphocytes. Merimepodib has the potential to exert direct antiviral activity, as well as affect the immune response by acting on lymphocyte migration and proliferation. Consequently, merimepodib may be an effective treatment for hepatitis C virus (HCV) infection, as the disease involves both viral proliferation and liver inflammation.

Mechanism of ActionMerimepodib is a orally active inhibitor of inosine monophospate dehydrogenase (IMPDH). IMPDH inhibition leads to a reduction in intracellular guanosine triphosphate (GTP), a molecule required for DNA and RNA synthesis.
Applications · 2 items

DescriptionMerimepodib is an inhibitor of inosine-5''-monophosphate dehydrogenase (IMPDH; Kis = 7 and 10 nM for IMPDH type I and type II, respectively) with antiviral and immunosuppressant activities. It reduces Ebola, Lassa, chikungunya, Junin, and Zika virus titers in vitro and inhibits Zika virus replication in Huh7 cells (EC50 = 0.6 μM). Merimepodib inhibits the proliferation of PHA-stimulated T cells and SPAS-stimulated B cells (IC50s = 104 and 132 nM, respectively), effects that can be reversed by guanosine but not adenosine . In vivo, merimepodib (50 and 100 mg/kg) increases allograft survival in a murine skin transplantation model and prevents development of graft versus host disease (GVHD) in splenocyte allografted mice.

UsesInhibition of inosine monophosphate dehydrogenase (IMPDH), which has potential antiviral, antiproliferative, antiparasitic, and immunosuppressive activity.

Related reactions

4 records
New reaction record
HRID 503970 reaction equation
HRID 503970As product
HRID 503971 reaction equation
HRID 503971As product
HRID 1984969 reaction equation
HRID 1984969As product
HRID 1984970 reaction equation
HRID 1984970As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes